Recomendado pelo AMICOR Eduardo de Azeredo Costa,
que há trinta anos já falava nisso.
Time to put eggs back on the menu? (Deb Lindsey for The Washington Post)
The nation’s top nutrition advisory panel has decided to drop its caution about eating cholesterol-laden food, a move that could undo almost 40 years of government warnings about its consumption.
The group’s finding that cholesterol in the diet need no longer be considered a “nutrient of concern” stands in contrast to the committee’s findings five years ago, the last time it convened. During those proceedings, as in previous years, the panel deemed the issue of excess cholesterol in the American diet a public health concern.
The finding follows an evolution of thinking among many nutritionists who now believe that, for healthy adults, eating foods high in cholesterol may not significantly affect the level of cholesterol in the blood or increase the risk of heart disease.
The greater danger in this regard, these experts believe, lies not in products such as eggs, shrimp or lobster, which are high in cholesterol, but in too many servings of foods heavy with saturated fats, such as fatty meats, whole milk, and butter./.../
*****************************
JAMA Clinical Guidelines Synopsis
February 4, 2019
Management of Blood Cholesterol
JAMA. Published online February 4, 2019. doi:10.1001/jama.2019.0015
Guideline title 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
Developers American Heart Association (AHA) and American College of Cardiology (ACC)
Release date November 10, 2018
Prior version 2013
Funding sources AHA/ACC
Target population Patients with or at risk of developing atherosclerotic cardiovascular disease (ASCVD)
Summary of the Clinical Problem
Pharmacologically lowering low-density lipoprotein cholesterol (LDL-C) consistently reduces ASCVD events (myocardial infarction, stroke, and cardiovascular death), and the principle that lower LDL-C is better was reaffirmed by trials that added ezetimibe or proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors to statin therapy.
1,2 The 2013 guideline removed specific LDL-C treatment targets, but high-quality trials since offered the opportunity to reintroduce such goals based on risk gradations.
Characteristics of the Guideline Source
This guideline was developed by the AHA and ACC in partnership with other professional societies,
3with a writing committee notable for wide scope of practice and lack of conflicts of interest, using an independent formal systematic review of recent large outcome trials of nonstatin lipid-modifying agents.
2 The overall quality of this guideline is high (eTable in the
Supplement).
No comments:
Post a Comment